IPP Bureau
India's healthcare policymakers call for digital health expansion and system strengthening
By IPP Bureau - May 01, 2026
Two-day long National Health Summit highlighted progress under the NHM and called for data-driven and SDG-aligned health system reforms
Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
By IPP Bureau - May 01, 2026
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Laurus Labs FY26 revenue rises 23% to Rs 6,813 Crore; EBITDA surges 64%
By IPP Bureau - May 01, 2026
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Fabtech Technologies FY26 revenue rises 28% to Rs 431 crore
By IPP Bureau - May 01, 2026
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
JP Nadda highlights India’s push for APIs, biologics and translational research
By IPP Bureau - May 01, 2026
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Cardioline expands global reach with strategic Cardios acquisition
By IPP Bureau - May 01, 2026
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
Merck KGaA launches Phase 3 push for lupus skin disease with enpatoran trials
By IPP Bureau - May 01, 2026
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
BD, Suttons Creek partner to streamline combination product development
By IPP Bureau - April 30, 2026
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
By IPP Bureau - April 30, 2026
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
GSK wins regulatory boost for once-monthly liver drug efimosfermin in MASH push
By IPP Bureau - April 30, 2026
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr
By IPP Bureau - April 30, 2026
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Sahajanand Medical Technologies secures ISO 50001:2018 certification for Surat, Hyderabad facilities
By IPP Bureau - April 30, 2026
Certification reinforces energy efficiency, sustainability goals, and green manufacturing across SMT’s Surat and Hyderabad facilities
Solara announces closure of US FDA inspection at Puducherry facility
By IPP Bureau - April 30, 2026
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Wanbury's Patalganga site clears Korea FDA inspection with zero observations
By IPP Bureau - April 30, 2026
Patalganga plant received zero observation from USFDA earlier
KIMS enters into MoU for strategic clinical collaboration
By IPP Bureau - April 30, 2026
The association is intended to strengthen healthcare delivery standards, particularly in Oncology services, and enhance patient care outcomes
